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Abstract Recent years showed significant progress in the
molecular characterization of the chronic myeloproliferative
disorders (CMPD) which are classified according to the
WHO classification of 2001 as polycythemia vera (PV),
chronic idiopathic myelofibrosis (CIMF), essential throm-
bocythemia (ET), CMPD/unclassifiable (CMPD-U), chron-
ic neutrophilic leukemia, and chronic eosinophilic leukemia
(CEL)/hypereosinophilic syndrome, all to be delineated
from BCR/ABL-positive chronic myeloid leukemia (CML).
After 2001, the detection of the high frequency of the
JAK2V617F mutation in PV, CIMF, and ET, and of the
FIP1L1–PDGFRA fusion gene in CEL further added
important information in the diagnosis of CMPD. These
findings also enhanced the importance of tyrosine kinase
mutations in CMPD and paved the way to a more detailed
classification and to an improved definition of prognosis
using also novel minimal residual disease (MRD) markers.
Simultaneously, the broadening of therapeutic strategies in
the CMPD, e.g., due to reduced intensity conditioning in
allogeneic hematopoietic stem cell transplantation and the
introduction of tyrosine kinase inhibitors in CML, in CEL,
and in other ABL and PDGRFB rearrangements, increased
the demands to diagnostics. Therefore, today, a multimodal
diagnostic approach combining cytomorphology, cytoge-
netics, and individual molecular methods is needed in BCR/
ABL-negative CMPD. A stringent diagnostic algorithm for
characterization, choice of treatment, and monitoring of
MRD will be proposed in this review.
Keywords CMPD.BCR/ABL.Molecularmarker.
Cytomorphology
Introduction
Chronic myeloproliferative disorders (CMPD) are clonal
stem cell disorders encompassing a very heterogeneous
complex of different entities which are defined by distinct
clinical and cytomorphological phenotypes and, in some
part, known genetic features. They are characterized by
increased and effective proliferation of one to three
hematopoietic cell lineages in the bone marrow associated
to increased peripheral blood parameters. The recent
detection of the high incidence of the JAK2 mutations in
polycythemia vera (PV), chronic idiopathic myelofibrosis
(CIMF), and essential thrombocythemia (ET) [1–5], the
detection of the FIP1L1–PDGFRA gene fusion in chronic
eosinophlilic leukemia (CEL) [6, 7], and the introduction of
tyrosine kinase inhibitors such as imatinib in chronic
myeloid leukemia (CML) or hypereosinophilic syndrome
(HES)/CEL shed new interest on molecular diagnostics and
detection of minimal residual disease (MRD) in CMPD.
Today, CMPD are primarily separated in CML as
defined by the Philadelphia translocation t(9;22)(q34;q11)/
BCR–ABL and in all other so-called BCR/ABL-negative
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latter are subdivided into PV, CIMF, ET, and unclassified
CMPD (CMPD-U). Some very rare disorders as chronic
neutrophilic leukemia (CNL), HES, and CEL are addition-
ally included. This broad spectrum becomes even more
heterogeneous due to the continuous progress of stages, as
all CMPD have the potential of clonal evolution and
stepwise progression. They often terminate in bone marrow
failure due to myelofibrosis or ineffective hematopoiesis or
in acceleration and finally transformation to blast crisis.
Differential diagnosis in CMPD is further hampered by the
biologically given overlap of the diverse morphologic
phenotypes and the sometimes close relationship to
reactive conditions, and even show overlaps to myelodys-
plastic disorders. The WHO, thus, created a category of
disorders combining myeloproliferative and myelodysplas-
tic features in which chronic myelomonocytic leukemia
(CMML), unclassified myelodysplastic/myeloproliferative
disorder (MDS/MPD, U), and some very rare disorders as
juvenile myelomonocytic leukemia (JMML) were incorpo-
rated [8, 9].
It is well known that PV has a median survival of
10 years, ET of 10–15 years, but CIMF of only 4 years.
However, the clinical course in CMPD ranges from a few
months with rapid leukemic transformation to several
decades. These uncertainties in prognosis and the similar-
ities in the clinical and morphological phenotypes at
diagnosis plead for inclusion of other than clinical and
morphologic parameters only into classification.
Although chromosomal abnormalities are not specific for
distinct CMPD, they contribute to the definition of the
prognosis and to the classification of the CMPD. However,
aberrant karyotypes are detectable in only 5–45% of all
BCR/ABL-negative CMPD, depending on the specific
subtype.
Routinely applied methods further include by now
polymerase chain reaction (PCR) screening for the V617F
mutation in the JAK2 non-receptor tyrosine kinase [1–5]
and will probably soon be included as diagnostic criteria in
a revised WHO classification of the CMPD [10]. This novel
marker is highly utile for the confirmation of a BCR/ABL-
negative CMPD and might contribute to the definition of
the prognosis and even for MRD strategies in the future
[11]. Molecular methods in the CMPD further encompass
PCR analyses of some rare gene fusions, e.g., in HES/CEL
[6, 7] or in the 8p11 syndrome [12].
Adaptation of these extensive diagnostic procedures in
CMPD to the laboratories’ resources becomes a major
challenge. Major goals are standardization of diagnostic
workflow, hierarchical order of methods, and combination
of single results. This review intends to propose specific
diagnostic algorithms for scenarios in BCR/ABL-negative
CMPD.
Preanalytic conditions
To achieve optimal conditions in the diagnostic procedures,
a standardized preparation of the samples and optimal
conditions for transport are essential in the CMPD:
Cytomorphology requires 3 ml bone marrow and 2 ml
peripheral blood anticoagulated with ethylenediaminetetra-
acetic acid (EDTA), being aware that cytomorphology is
hampered by heparine. Cytogenetics, in contrast, requires
5–10 ml heparinized bone marrow and 10–20 ml heparin-
ized peripheral blood, as cultivation of metaphases is nearly
inhibited by EDTA which induces apoptosis of cells.
Multiparameter flow cytometry and all molecular genetic
methods can be performed either on EDTA or heparinized
material. Trephine biopsies should be performed for
histomorphology and immunohistochemistry and allow
cytomorphological evaluation by smears from the trephine
cylinder in case of a dry tap. In the latter case, also for
cytogenetics, a trephine cylinder can be transferred to
isotone saline solution plus heparine, which, in many cases,
makes metaphases after cultivation in cytogenetic medium
possible.
Cytomorphology in CMPD
Differential diagnosis in the CMPD should always include
investigation of peripheral blood smears, bone marrow
aspirates, and trephine biopsies in parallel. Smears from
peripheral blood and bone marrow are stained according to
May Grunwald Giemsa. This may be completed by other
stainings: Myeloperoxidase (MPO) reaction and non-spe-
cific-esterase (NSE) should be performed in blast crisis
after CMPD and are warranted in cases of CMML. Iron
staining may be performed additionally, but is of minor
importance for the differential diagnostics, as in an early
PV, iron will not always be absent. MPO and iron staining
are further helpful in all cases with an overlap between the
CMPD and MDS for detection of MPO deficiency and
ringed sideroblasts. Cases with suspicious HES or CEL
should, in addition, undergo toluidine blue staining for
detection of mast cells which are frequently increased in
CEL with the FIP1L1–PDGFRA gene fusion.
In PV, cytomorphology shows increased cellularity with
trilineage cell proliferation. Stainable iron is completely
missing in many cases. PV is further characterized by
elevated blood counts in either cell line (Hb>18.5 g/dl in
men, >16.5 g/dl in women, platelets ≥400×10
9/l, WBC
≥12×10
9/l). In addition, other criteria as reduced serum
erythropoietin levels below normal ranges [10, 13]o ri n
vitro formation of endogenous erythroid colonies are
included in the classification criteria [8]. In CIMF, bone
marrow cytology is often hampered by myelofibrosis, and
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tosis and leukoerythroblastosis. However, these findings are
not specific but occur as well in secondary myelofibrosis
following other CMPD. ET is characterized by proliferation
of the megakaryocytic lineage with clusters of enlarged
mostly mature megakaryocytes in normocellular bone
marrow. Granulopoiesis and erythropoiesis present as
normal. According to the WHO [8], a diagnosis of ET
requires a sustained peripheral platelet count ≥600×10
9/l,
whereas reactive thrombocytosis must be excluded. Re-
cently, an international expert panel recommended to lower
the threshold for the diagnosis of ET to 450×10
9/l [10]. All
CMPD, but especially CML, may show the so-called
pseudo-Gaucher cells in the bone marrow, which represent
glycolipide storing histiocytes resulting from increased cell
proliferation [14]. Another specific cytomorphological
subentity is represented by refractory anemia with ringed
sideroblasts associated with marked thrombocytosis >500×
10
9/l (RARS-T). This rare subtype may be included within
the category of overlapping myelodysplastic and myelo-
proliferative diseases in the upcoming WHO classification
[15–17].
Histomorphology in CMPD
Bone marrow histology has a central role in the diagnosis
of CMPD. Staining is performed according to Giemsa,
PAS, and chloroacetate esterase. Gomori silver impregna-
tion allows assessment of reticulin fibers to quantify bone
marrow connective tissue.
Thus, a diagnosis of CIMF requires at least a bone
marrow histology, as bone marrow aspirates are hampered
in most cases. Histology shows variable reticulin or
collagen fibrosis, osteosclerosis, and sometimes even
decreased cellularity. Sinuses are dilated with intraluminal
hematopoiesis and erythrocyte extravasates. Megakaryopoi-
esis is increased with signs of dysplasia [8, 18].
PV demonstrates increased megakaryopoiesis, increased
granulopoiesis, and erythropoiesis without storage iron,
sinusoid hyperplasia, and variable myelofibrosis in combi-
nation with osteopenia. These characteristics allow discrim-
ination from reactive erythrocytosis [19]. In more detail,
differentiation from cases of secondary polycythemia
includes the evaluation of megakaryopoiesis which shows
clustering and pleomorphous appearance with very small
and giant megakaryocytes with the characteristical stag-
horn-like nuclei neighboring each other [19, 20].
ET is characterized by clusters of enlarged mature
megakaryocytes close to the sinusoids, whereas erythropoi-
esis and granulopoiesis are normal [10, 18]. A specific
problem is provided by the differentiation between ET and
prefibrotic CIMF, as both might be characterized by
thrombocytosis in initial stages, and reticulin fibrosis might
be minimal or absent in prefibrotic CIMF. However,
prefibrotic CIMF is characterized by marked hypercellular-
ity, left-shifted increased granulopoiesis, and a particular
megakaryocyte morphology with nuclear features, whereas
ET shows hyperlobulated and mature-appearing megakar-
yocytes [10, 21].
Cytogenetics in BCR/ABL-negative CMPD
The frequency of clonal karyotype anomalies varies
considerably between the different BCR/ABL-negative
CMPD entities. The presence of karyotype abnormalities
at diagnosis per se seems to be prognostically negative [9].
CIMF has the highest karyotype aberration rate with 33–
43% of all cases, followed by PV in 33–35%, whereas in
ET, clonal abnormalities are extremely rare (<5%) [22–25].
In CMPD-U, aberrant karyotypes were reported in ∼20%
[22], but definition of the true incidence is difficult due to
the heterogeneity of subtypes in this category.
Chromosomal changes in the CMPD are not specific, but
their presence at least confirms the diagnosis of a malignant
hematopoietic disorder and contributes additional aspects to
differential diagnosis. This can be exemplified in the 9p-
aberrations which are closely associated to PV and to
CIMF. In addition, translocations involving ABL, PDGFRA,
PDGFRB or other tyrosine kinases can be detected by
chromosome banding analyses, allowing the identification
of patients who probably benefit from treatment with
tyrosine kinase inhibitors.
Thus, chromosome banding analyses contribute a lot at
diagnosis in many in cases with a suspicious or proven
CMPD. However, they do not lead to important information
for clinically clearly proven cases of ET. Cytogenetics may
also be needed for the follow-up of the CMPD, as leukemic
transformation is characterized in many cases by clonal
evolution to more complex karyotypes resulting in higher
rates of chromosomal abnormalities of ≥90% [9, 23, 26].
Interphase (IP-), metaphase (HMF-), and 24-color
fluorescence in situ hybridization (FISH) may further
confirm and clarify the results of the chromosome banding
analyses. IP-FISH probes can be used for future MRD
studies. Nearly all typically observed aberrations—e.g., +8,
+9, gain of 9p, or del(20q)—can be monitored.
Trisomy 8 is the most frequent aberration in the CMPD
being detected in ∼20% of all cytogenetic aberrant PV
cases and in ∼10% in chromosomally aberrant CIMF—
mostly as sole abnormality or in combination with +9. This
is followed by trisomy 9 in ∼10% of all cytogenetically
aberrant cases. Partial trisomies of 9p are equally frequent
with a special association to PV [27–30]. Other recurrent
aberrations are deletions of 13q and 20q and partial
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(12p), and i(17q) are less frequent.
Chromosomal changes show a characteristic distribution
within the diverse CMPD. In detail, PV shows, as the most
frequent changes, +9, followed by +8 and by del(20q) [23,
26]. CIMF has a more heterogeneous pattern with deletions
of 13q and of 20q both in ∼9% of all cases [9, 25],
structural abnormalities of 1q and 5q, and chromosome 7
abnormalities [23, 31]. In ET, chromosomal abnormalities
are found in <5% of cases only, mostly represented by
numerical gain of chromosome 9. Table 1 presents an
overview on recurrent cytogenetic and molecular markers
in the CMPD.
Balanced translocations as revealed by cytogenetics are
rare in the CMPD. Many of these lead to the disruption of
genes encoding tyrosine kinases. The breakpoints cluster in
two regions at 5q31-33 and 8p11 which target the platelet-
derived growth factor receptor beta [e.g., in the t(5;12)
(q31q33;p12)/ETV6-PDGFRB)] and the fibroblast growth
factor receptor 1 kinase [e.g., in t(8;13)(p11;q12)/FGFR1-
ZNF198)]. Further, the ABL non-receptor tyrosine kinase
might be involved in these rare rearrangements as in the
t(9;12)(q34;p13)/ETV6-ABL [32]. The 8p11 myeloprolifer-
ative syndrome shows a specific profile outlined by
frequent association to Non-Hodgkin’s lymphoma, high
leukemic transformation rates, eosinophilia, and CML-like
findings in bone marrow cytomorphology. It is most
frequently caused by the t(8;13)(p11;q12)/FGFR1-ZNF198,
but many other variants all involving 8p11/FGFR1 have
been described. Bone marrow cytomorphology shows
CML-like findings and eosinophilia [12]. As patients with
PDFRB and ABL rearrangements are all candidates for
tyrosine kinase inhibitor treatment, detection of these rare
rearrangements by cytogenetics in combination with FISH
and PCR is obligatory. For an overview on these reciprocal
gene fusions, we refer to Cross and Reiter [32].
Molecular mutations in BCR/ABL-negative CMPD
As published in 2005 by several study groups, a high
proportion of patients with BCR/ABL-negative CMPD have
a somatic point mutation in the JAK2 gene on 9p24 (V617F)
which codes for the JAK2 kinase. In detail, the mutation was
found in 80–97% of all patients with PV, in >50% of all
patients with CIMF, and in 40–57% in ET [1–5]. Janus
kinases are non-receptor TKs which regulate the phosphor-
ylation of several signaling pathways, e.g., JAK/STAT,
whose activity is increased by the JAK2 mutation [3, 5].
Interestingly, JAK2V617F-positive ET cases were found to
show considerable clinical similarities to PV. This pleads for
common pathogenetic pathways in part of the ET cases and
in PV [33]. It has to be expected that the JAK2V617F
mutation will soon be included as a major criterion for PV
diagnosis in a revised WHO classification, as nearly all cases
were found to be positive [10]. According to this proposal,
also in ET or in CIMF, the respective mutation will serve
likewise to any other clonal marker as criterion for the
diagnosis of ETor CIMF, which further emphasizes its value
for diagnostics in the CMPD.
A positive mutation status seemed correlated with further
advanced stages. Homozygous JAK2 mutations are more
frequent in PV and CIMF than in ET [26]a n da r e
associated with a longer history of disease than heterozy-
gous mutations [34]. Thus, a homozygous mutation status
correlates with a more aggressive course and might indicate
an inferior outcome.
Different assays were developed for JAK2 mutational
analyses, e.g., allele specific PCR, real-time PCR, or
pyrosequencing, which is able to convey information on the
frequency of mutated alleles [35]. Kroger et al. [11]s h o w e d
that quantitative assessment of the JAK2 mutation with real-
time PCR after allogeneic hematopoietic stem cell transplan-
tation was valid as minimal residual disease parameter
Table 1 Chromosomal and
molecular markers in CMPD
[8, 9, 22, 23, 52, 69]
Karyotype abnormalities Molecular markers Molecular MRD
markers
CML t(9;22)(q34;q11), in all cases
BCR–ABL
BCR/ABL +
PV In some cases: +8, +9, del(20q),
del(13q), del(1p)
JAK2V617F +
JAK2 exon 12 in
V617F-negative cases
CIMF In some cases: del(13q), del(20q),
+8, +9, partial trisomy 1q
JAK2V617F +
MPLW515
ET In rare cases +8, +9, del(13q), JAK2V617F +
MPLW515
CMPD-U In some cases +8, +9, del(20q) JAK2V617F +
In rare cases 8p11 translocations FGFR1 rearrangements
CEL/HES in some cases: +8, i(17q), PDGFRA/FIP1L1 in CEL +
CNL in some cases: +8, +9, del(20q) −−
CMML −7, +8, del(20q) NRAS in some cases +
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ingly. Thus, determination of the JAK2V617F mutation
status is highly valuable for all cases with a suspicious or
proven BCR/ABL-negative CMPD and even contributes to
determination of the prognosis and to MRD strategies.
The role of the JAK2V617F mutation is not limited to
the “classical” CMPD but was detected in other myeloid
malignancies as well, e.g., in 3–10% of all MDS cases [1,
36, 37]o ri n5 0 –90% in RARS-T representing an
ambiguous subentity with overlapping myeloproliferative
and myelodysplastic features [17, 38]. Interestingly, the
JAK2V617F mutation was as well found in 20–30% of
patients with abdominal vein thromboses and in 5% of
patients with cerebral vein thromboses without signs of an
overt hematologic disorder [39, 40].
Since the detection of the JAK2617F, the panel of known
activating mutations in the CMPD is continuously increas-
ing: PV patients who were JAK2V617F-negative were
detected to carry somatic gain-of-function mutations within
exon 12 of the JAK2 gene in 40% of cases in a recent study.
This mutation subtype was shown to stimulate erythroid
proliferationininvitroexperiments[40, 41]. Further on, ∼5%
of CIMF and ∼1% of all ET cases show somatic mutations
in codon 515 within the transmembrane domain of the MPL
gene which encodes the thrombopoietin receptor. The
respective point mutations lead to single amino exchanges
(W515L and W515K) and induce constitutive cytokine-
independent activation of the JAK-STAT pathway as gain-
of-function-mutations likewise to the V617F [42–44].
Chronic neutrophilic leukemia
CNL is a very rare CMPD defined by persistent leukocy-
tosis in pB ≥25×10
9/l, segmented neutrophils and bands
>80% of WBC, immature WBC <10%, and myeloblasts
<1% [8]. Survival is extremely heterogeneous and was
reported from a few months to 20 years. Cytogenetic
aberrations are rare and include +8, +9, del(20q), and del
(11q) [8, 45, 46]. The JAK2 mutation was described in few
cases of CNL [4, 22, 37, 45–48], but determination of the
true incidence is extremely difficult due to the rare
occurrence. Some CNL cases were identified to bear rare
BCR–ABL fusion transcripts with a breakpoint between
exons c3 and c4 of the BCR gene leading to a 230-kDa
fusion protein [49, 50].
Hypereosinophilic syndrome/chronic eosinophilic
leukemia
Persisting hypereosinophilia is, in most cases, reactive and
is only rarely caused by a malignant disorder such as HES
or CEL orother eosinophilia-associated CMPD [6, 7, 51–53].
HES is defined by persistent eosinophilia ≥1.5×10
9/l in
peripheral blood >6 months and an increased number of
bone marrow eosinophils of unknown origin; this is
accompanied by organ involvement and dysfunction. Clas-
sification as HES requires exclusion of all other causes and
failure of detection of the underlying genetic defect by
cytogenetic and/or molecular screening.
A diagnosis of CEL requires >2% blasts in peripheral
blood and >5–19% bone marrow blasts or evidence of
clonality [8, 54]. The most frequent aberration in CEL is
the FIP1L1–PDGFRA fusion which results from a cryptic
interstitial deletion on chromosome 4q12. Whereas chro-
mosome banding analyses fail to detect the respective
cytogenetic correlate, it is revealed by IP-FISH with
differently marked probes for CHIC2, FIP1L1,a n d
PDGFRA, and with reverse transcription (RT)-PCR for
FIP1L1–PDGFRA [55, 56].
Some more rare TK gene fusions were detected in
eosinophilia-associated CMPD, which involve the tyrosine
receptor kinases PDGFRA on 4q12, PDGFRB on 5q31,
FGFR1 on 8p11, and the non-receptor kinase JAK2 on
9p24 [9, 57]. The beneficial response of patients with
PDGFRA and PDGFRB rearrangements to imatinib makes
the detection of these rearrangements obligatory [6, 7, 53,
58]. Therefore, a combination of cytomorphology, cytoge-
netics, IP-FISH, and RT-PCR based on the patient’s history
provides the basis for optimized diagnosis in eosinophilia-
associated CMPD followed by targeted therapy [32, 59, 60].
Chronic myelomonocytic leukemia
Due to its ambiguous character, CMML was incorporated
by the WHO into a category which overlaps between
myelodysplastic and myeloproliferative disorders [8] and
was defined by peripheral monocytes >1×10
9/l and by
dysgranulopoiesis >10%. Blasts and promonocytes were
defined by <20% of WBC and by <20% of all nucleated
cells in bone marrow. NSE was strongly recommended for
bone marrow examination. Clonal karyotype abnormalities
occur in 25–35% of all cases. Most frequent are changes of
chromosome 7, trisomy 8, and complex aberrant karyotype
which is defined by three or more chromosomal aberrations
[9, 22, 61]. Mutations of the NRAS protooncogene are the
most frequent so far identified molecular markers with
variable incidences of 10–66% in this entity. Although
there was a wide range in these studies (probably due to the
limited samples size in the different studies), this high
incidences suggest parallels to MDS or AML [61–63]. The
JAK2 mutation was detected in 3–13% of all cases with
CMML [1, 4, 37], which illustrates the vicinity to the
CMPD in another part of CMML cases. This molecular
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diversity of CMML and supports the ambiguous position as
suggested in the WHO classification.
Remission criteria in the CMPD
New therapeutic strategies including allogeneic stem cell
transplantation as potentially curative option or targeted
therapies in the CMPD implicate the need for more
differentiated and sensitive criteria of remission. For CIMF,
an international working group formulated new consensus
criteria for response to treatment [64]. These criteria are
based on a combination of clinical and laboratory param-
eters and include cyto- and histomorphological, cytogenet-
ic, and molecular findings. Thus, highest so far applicable
sensitivity is achieved. Clinical criteria include disappear-
ance of clinical symptoms as palpable hepatosplenomegaly.
The laboratory and cytomorphological criteria of complete
remission imply normalization of trilineage peripheral
blood count and the absence of blasts, immature progenitor
cells, or nucleated erythroid precursors in peripheral blood.
Bone marrow histologic remission criteria apply to cellu-
larity, myeloblast percentage, and osteomyelofibrosis. Fi-
nally, cytogenetic response criteria discriminate major
cytogenetic response, meaning absence of chromosomal
abnormalities in cases with a preexisting aberration from
minor cytogenetic response requiring a ≥50% reduction of
abnormal metaphases. As the most sensitive criterion, major
molecular response defines absence of a specific disease-
associated mutation in previously positive cases [64].
Approach to a diagnostic algorithm in the CMPD
A diagnostic algorithm for all cases with diagnosis or
suspicion of CMPD (Fig. 1) should start with the cytomor-
phologic evaluation of peripheral blood and bone marrow.
This allows, in many, cases a differentiation between CML
and a BCR/ABL-negative CMPD. In parallel, all cases
should be evaluated by histomorphology.
Chromosome banding analyses might gain important
information in PV, CIMF, and also in CMPD-U, as
chromosomal aberration rates of ∼20–45% were reported
[22]. According to the recent guidelines of a British
Committee, cytogenetics are considered as “stage 2 inves-
tigations” in case of PVand erythrocytosis which should be
performed in dependence on the results of clinical evalu-
ation, blood count, and the JAK2 mutation as well as other
laboratory parameters such as serum ferritin which are
IP-FISH or PCR: BCR-ABL
(exclusion of CML)
PV
Cytomorphology and Histomorphology
ET CIMF CMPD-U
Chromosome banding analysis
HES / CEL
IP-FISH for CHIC2
+ RT-PCR: 
FIP1L1-PDGFRA
8p11 syndrome
other rec.  rearrangements
PCR: PDGFRB, FGFR,…
blast phase: 
+MFC
IP-FISH 
(20q-, +8, +9,..)
PCR: JAK2V617F
Suspicion of
CMML
PCR: 
NRAS
V617F-negative cases: 
PV: JAK2 exon 12
ET, CIMF: MPLW515
RARS-T
Exclusion of reactive conditions
Clinical / hematological parameters
Fig. 1 Proposal for a diagnostic algorithm in BCR/ABL-negative
CMPD. HES Idiopathic hypereosinophilic syndrome, CEL chronic
eosinophilic leukemia, PV polycythemia vera, CIMF chronic idio-
pathic myelofibrosis, CMPD-U unclassifiable CMPD, ET essential
thrombocytosis, RARS-T refractory anemia with ringed sideroblasts,
CMML chronic myelomonocytic leukemia, MFC multiparameter flow
cytometry, RT-PCR reverse transcription polymerase chain reaction.
Dashed line may add information in difficult cases, but not obligatory
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cytogenetics can be neglected in clinically clear cases of ET
due to the extremely low incidence of aberrant karyotypes.
In cases in which the discrimination of a CMPD from a
reactive disorder is not possible according to clinical,
laboratory, and cyto-/histomorphological aspects, cytoge-
netics might contribute to differential diagnosis, as, in some
cases, clonal abnormalities confirm the diagnosis of a
hematologic malignancy. CMML should as well undergo
cytogenetic analyses; in addition, molecular screening for
NRAS mutations might be discussed due to their frequent
occurrence and new drugs that may come up. This also
includes the investigation of PDGF receptors expression.
The chromosomal aberrations as revealed by chromo-
some banding analyses—e.g., +8, +9, del(20q)—can be
verified by FISH techniques. This further allows the
selection of IP probes for distinct numerical and structural
aberrations to provide parameters for MRD diagnostics.
Today, the backbone in all cases of suspicious or proven
CMPD should be screening for the JAK2V617F mutation
status by PCR, e.g., by a melting curve light cycler assay
[66]. According to the proposals for a revised WHO
classification, evidence of the JAK2V617F mutation (local-
ized in exon 14 of the JAK2 gene) or a functionally similar
mutation will be required as major criterion for the
diagnosis of PV. This might justify additional screening
for JAK2 mutations in exon 12 in cases which are highly
suspicious for PV from morphological aspects but are
negative for the JAK2V617F [10].
Finally, all cases with a suspected or proven CMPD
should be evaluated by IP-FISH or PCR for BCR–ABL to
exclude a diagnosis of CML due to the therapeutic
consequences. This is even more emphasized by single
cases showing a coincidence of the BCR–ABL fusion and
the JAK2V617F mutation where the cytomorphological
features of the CMPD can mask the CML aspect [67].
In cases with diagnosis or suspicion of HES/CEL,
cytogenetic analysis is informative only in very few cases
and may be omitted, whereas molecular diagnostics in
search of the FIP1L1–PDGFRA gene fusion by IP-FISH
and/or RT-PCR is obligatory.
Conclusions
For many years, diagnostics in the BCR/ABL-negative
CMPD were mainly based on clinical symptoms, cytomor-
phology, and histomorphological findings. This has dra-
matically changed in recent years. The WHO (2001) [8]
included cytogenetic aspects directly and indirectly in their
classification system. This can be exemplified in ET which
is excluded by evidence of a del(5q) or an inv(3)(q21q26),
as both the 5q- syndrome in MDS or AML with the
respective inversion 3 can show microkaryocytes and high
thrombocytes. Clonal chromosomal abnormalities other
than the Philadelphia translocation support the diagnosis
of CMPD and allow to discriminate this from reactive
conditions.
Additionally, the spectrum of molecular mutations
considerably increased. Most molecular events target
receptor TK (such as FGFR1, PDGFRA, and PDGFRA)
and non-receptor-TK (such as ABL or JAK2). Especially,
the detection of the JAK2 mutation in the majority of
patients with a CMPD has revolutionized diagnostics in the
CMPD [13] and allows, in many cases, now a rapid and
clear discrimination of the CMPD from reactive conditions.
It further may abolish the measurement of the PRV1
expression in cases with suspected PV. JAK2 mutated cases
seem to be associated with higher complication rates and an
increased need for therapeutic interventions when com-
pared to wild-type patients [3]. This might play a role for
the choice of therapy in the future. Finally, JAK2 might
represent a target for specific compounds with anti-tyrosine
kinase activity [2, 34]. The recent description of JAK2
mutations in exon 12 in V617F-negative PV cases [40, 41]
and of the W515 mutations of the MPL gene in a low
frequency in ET and CIMF [42–44] illustratethat wehaveto
assume a complex network of activating mutations in the
CMPD of which only parts are so far identified. Thus, a new
classification of the CMPD according to the molecular
substrate, e.g., the JAK2 mutation, likewise to the definition
of CML, will be more appropriate [10, 68]. The inclusion of
JAK2 mutation analysis as a major criterion for the PV
diagnosis within the current and upcoming World Health
Organization (WHO) diagnostic criteria was suggested [10].
The detection of the FIP1L1–PDGFRA fusion in CEL/
HES in association to the good response to imatinib [6, 52]
and the increasing detection of rare fusion transcript in the
BCR/ABL-negative CMPD [32] contributed as well signif-
icantly to an improved molecular classification in CMPD.
MRD strategies are so far poorly established in the
Philadelphia negative CMPD when compared to the acute
leukemias or to CML. This might change in the near future,
as it was already shown in a post-transplantation setting that
quantitative assessment of the JAK2 mutation qualifies as
MRD marker [11]. In CML, the definition of remission
criteria allowed an international standardization in clinical
studies and was helpful for clinical routine. This approach
is increasingly important also for the BCR/ABL-negative
CMPD as realized by an international working group
proposing cytogenetic and molecular response criteria in
CIMF [64].
In conclusion, diagnostics in the BCR/ABL-negative
CMPD have abandoned the former perception which
classified these complex disorders mainly on clinical and
morphological aspects and are on the way to a comprehen-
Ann Hematol (2008) 87:1–10 7sive approach focussing increasingly on cyto- and molec-
ular genetic aspects. Individual treatment is already avail-
able or will hopefully follow.
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